Advances and Innovations in Hypertrophic Cardiomyopathy Management: A Focus on New and Emerging Therapies

This activity was originally presented at the 2025 PTCE Cardiology Day of Education.

Program Description

Hypertrophic cardiomyopathy (HCM) is a common cardiovascular disease characterized by abnormally thick or enlarged heart muscle and left ventricular hypertrophy. The disease often goes undiagnosed, and conventional therapies for symptomatic HCM are often inadequate and poorly tolerated. Recently, newly approved and investigational cardiac myosin inhibitors have emerged for the treatment of symptomatic HCM. Pharmacists must be familiar with the clinical application of these therapies, as well as their role within recent updates to guidelines for the diagnosis and management of HCM. This session will review the impact of early detection of HCM in reducing disease burden as well as patient-centered interventions that pharmacists can incorporate into treatment plans to improve clinical outcomes. Featured patient case discussions will allow participants to evaluate shared clinical decision-making for treatment initiation, consider the potential place in the treatment paradigm for emerging therapies, and practice solutions for current challenges in the management of therapies for patients with HCM.

Target audience: Ambulatory Care Pharmacist, Health System Pharmacist, Specialty Pharmacist

Type of activity: Application
Release date: June 13, 2025
Expiration date: June 13, 2026

Time to complete activity: 1.5 hours

Learner level: Foundational, Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

1. Analyze the underlying pathophysiology, prevalence, and risk factors of hypertrophic cardiomyopathy (HCM), along with its associated comorbidities, to understand their collective impact on patient health and quality of life
2. Examine the mechanisms of action, efficacy, and safety profiles of novel and emerging cardiac myosin inhibitors to determine their appropriate use in the treatment and management of HCM
3. Assess the 2024 ACC/AHA guidelines updates for the management of HCM to guide evidence-based clinical decision-making and optimize patient care strategies
4. Investigate the pharmacist’s role in interdisciplinary teams to develop patient-centered treatment plans for HCM and provide comprehensive counseling and monitoring to optimize therapeutic outcomes and patient adherence